14.47USD+2.26%Mkt Cap: 31.78M USDP/E: —Last update: 2026-06-01
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The comp…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap31.78M USD
Enterprise Value28.44M USD
Revenue (TTM)8.84M USD
Gross Profit8.84M USD
Net Income (TTM)-10.94M USD
Revenue/Share6.115 USD
Last Price14.47 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-21.77
PEG—
EV/EBITDA-3.13
EV/Revenue3.22
P/S3.51
P/B-9.53
EPS (TTM)-7.57
EPS (Forward)-0.65
52W Range
3.65928% of range42.12
52W High42.12 USD
52W Low3.659 USD
Profitability
Gross Margin100.00%
Oper. Margin431.87%
EBITDA Margin-102.75%
Profit Margin-128.69%
ROE343.13%
ROA-162.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.37M USD
CapEx (TTM)—
FCF Margin-110.93%
FCF Yield-30.87%
Net Debt-2.63M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity-0.20
Current Ratio0.96
Quick Ratio0.91
Book Value/Sh-1.4850 USD
Cash/Share1.492 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateNov 25, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.20M
Float1.26M
Insiders53.32%
Institutions0.03%
Short Interest
Short Ratio0.6d
Short % Float0.29%
Short % Out.0.15%
Shares Short3.26K
Short (prev mo.)6.09K
Technical
SMA 5015.01 (-3.6%)
SMA 20016.37 (-11.6%)
Beta1.52
S&P 52W Chg27.94%
Avg Vol (30d)6.87K
Avg Vol (10d)10.20K
Technical Indicators
RSI (14)47.0
MACD-0.2411
MACD Signal-0.2660
MACD Hist.+0.0249
BB Upper16.54 USD
BB Middle14.73 USD
BB Lower12.93 USD
BB Width24.48%
ATR (14)1.153 USD
Vol Ratio (20d)2.90x